PYC THERAPEUTICS LIMITED - Announcements

4.15%

$1.27

Market Cap $740.7M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

Actinogen Medical (ASX:ACW) reaches 100th participant milestone in Alzheimer’s Disease Trial & confirms interim analysis timeline.

Announcements

Filter Results

All Price Sensitive Only

PYC	Q1 Investor Call 17 February 2023		10/02/23	188.48KB	Share
PYC	PYC Corporate Presentation - February 2023		03/02/23	2.82MB	Share
PYC	VP-001 IND Lodgement	PRICE SENSITIVE	02/02/23	158.05KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/01/23	223.22KB	Share
PYC	Notification of cessation of securities - PYC		21/12/22	23.83KB	Share
PYC	PYC Increases Ownership of VP-001 Program	PRICE SENSITIVE	29/11/22	163.64KB	Share
PYC	Results of Annual General Meeting		23/11/22	243.99KB	Share
PYC	2022 AGM Chairman's Address and CEO Presentation		23/11/22	1.76MB	Share
PYC	Annual General Meeting - Conference Call		21/11/22	160.78KB	Share
PYC	Successful Toxicology Studies Pave Way for Human Trials	PRICE SENSITIVE	07/11/22	223.45KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	446.75KB	Share
PYC	Issue of Options		28/10/22	322.61KB	Share
PYC	Notification regarding unquoted securities - PYC		28/10/22	27.57KB	Share
PYC	Notice of Annual General Meeting/Proxy Form		14/10/22	832.75KB	Share
PYC	PYC Presenting on Drug Delivery Platform at OTS 2022 Meeting		03/10/22	201.51KB	Share
PYC	Central Nervous System Drug Program Added to PYC Pipeline	PRICE SENSITIVE	27/09/22	256.59KB	Share
PYC	Corporate Governance Statement and Appendix 4G		23/09/22	670.25KB	Share
PYC	Annual Report to shareholders		23/09/22	2.41MB	Share
PYC	Preliminary Final Report	PRICE SENSITIVE	31/08/22	788.67KB	Share
PYC	PYC Shareholder Update		18/08/22	603.36KB	Share
PYC	Change of Director's Interest Notice		11/08/22	267.27KB	Share
PYC	PYC Therapeutics Investor Call - 18 August 2022		09/08/22	193.48KB	Share
PYC	Change of Director's Interest Notice		04/08/22	267.27KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/07/22	231.28KB	Share
PYC	Share Trading Policy		28/06/22	426.93KB	Share
PYC	Corporate Presentation - May 2022		31/05/22	728.83KB	Share
PYC	PYC Q2 Investor Call - 31 May 2022		27/05/22	191.43KB	Share
PYC	PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS		10/05/22	213.56KB	Share
PYC	Appendix A Terms and Conditions of Options		04/05/22	123.22KB	Share
PYC	Notification regarding unquoted securities - PYC		04/05/22	27.68KB	Share
PYC	Issue of Options		04/05/22	179.56KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	238.74KB	Share
PYC	Completes FDA Pre-IND engagement - RP11 program		23/03/22	190.45KB	Share
PYC	Q1 Investor Call Presentation		17/03/22	278.21KB	Share
PYC	Quarterly Investor Call March 2022		08/03/22	161.84KB	Share
PYC	Notification regarding unquoted securities - PYC		01/03/22	27.41KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	2.31MB	Share
PYC	PYC Increases Shareholding in Vision Pharma	PRICE SENSITIVE	17/02/22	161.82KB	Share
PYC	Becoming a substantial holder		02/02/22	310.61KB	Share
PYC	Quarterly Activities and Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	212.81KB	Share
PYC	Notification of cessation of securities - PYC		07/01/22	21.75KB	Share
PYC	Change in substantial holding		29/12/21	538.01KB	Share
PYC	Change of Registry Address		20/12/21	152.9KB	Share
PYC	Notification of cessation of securities - PYC		09/12/21	21.73KB	Share
PYC	Appendix C US Sub Plan		30/11/21	156.65KB	Share
PYC	Appendix B Terms and Conditions of Options		30/11/21	136.4KB	Share
PYC	Appendix A Terms and Conditions of Options		30/11/21	136.28KB	Share
PYC	Notification regarding unquoted securities - PYC		30/11/21	30.48KB	Share
PYC	Notification of cessation of securities - PYC		29/11/21	21.69KB	Share
PYC	Final Director's Interest Notice		25/11/21	287.11KB	Share
PYC	Results of 2021 Annual General Meeting		18/11/21	159.65KB	Share
PYC	2021 AGM Chairman's Address and CEO Presentation		18/11/21	294.09KB	Share
PYC	Annual General Meeting - Conference Link		17/11/21	161.93KB	Share
PYC	Successful Completion of Key Translational Milestone	PRICE SENSITIVE	16/11/21	190.99KB	Share
PYC	Trading Halt	PRICE SENSITIVE	15/11/21	186.73KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	287.47KB	Share
PYC	Notice of Annual General Meeting/Proxy Form		19/10/21	1.08MB	Share
PYC	Retina Target Engagement Confirmed in Large Eye	PRICE SENSITIVE	29/09/21	316.13KB	Share
PYC	Corporate Governance Statement and Appendix 4G		22/09/21	669.27KB	Share
PYC	Annual Report to shareholders		22/09/21	1.72MB	Share
PYC	Upcoming Poster Presentations at TIDES USA and OTS 2021		21/09/21	175.71KB	Share
PYC	Oppenheimer Fall Healthcare Life Sciences & MedTech Summit		15/09/21	158.31KB	Share
PYC	Preliminary Final Report	PRICE SENSITIVE	31/08/21	3.64MB	Share
PYC	August Investor Update		17/08/21	1.51MB	Share
PYC	Ophthalmology-Focused Clinical Advisory Board		17/08/21	174.51KB	Share
PYC	PYC Quarterly Investor Call - August 17		11/08/21	191.28KB	Share
PYC	Participation in Upcoming U.S. Investor Conferences		03/08/21	160.06KB	Share
PYC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	407.7KB	Share
PYC	Commencement of Larger Animal Studies for Lead Program		14/07/21	160.02KB	Share
PYC	Change of Auditor		01/07/21	145.35KB	Share
PYC	VP-002 Program - Technical Presentation		29/06/21	864.11KB	Share
PYC	Exercise of Options		15/06/21	281.94KB	Share
PYC	Application for quotation of securities - PYC		15/06/21	25.34KB	Share
PYC	New U.S. Headquarters, and Residency at JLABS		15/06/21	163.29KB	Share
PYC	Second Drug Program Progressing Towards Human Trials	PRICE SENSITIVE	08/06/21	389.99KB	Share
PYC	Trading Halt	PRICE SENSITIVE	07/06/21	613.05KB	Share
PYC	Evercore ISI GenomeRx Emerging Therapeutic Company Day		26/05/21	157.21KB	Share
PYC	SECOND DRUG PROGRAM - EFFICACY DATA IN PATIENT CELL MODELS		18/05/21	289.67KB	Share
PYC	PYC Invited to Present at ARVO 2021 Annual Meeting		04/05/21	175.83KB	Share
PYC	Set To Announce Efficacy Results For Second Drug Program		03/05/21	193.64KB	Share
PYC	March 2021 Quarterly Report and Cashflow	PRICE SENSITIVE	30/04/21	311.12KB	Share
PYC	Corporate Presentation April 2021		22/04/21	2.57MB	Share
PYC	April Investor Call Presentation		15/04/21	7.45MB	Share
PYC	Preclinical Data - Superior PPMO Delivery to the Brain		12/04/21	2.68MB	Share
PYC	Quarterly Investor Call - 15th April 2021		06/04/21	157.67KB	Share
PYC	Appendix 3X - Initial Director's Interest Notice		30/03/21	302.3KB	Share
PYC	Appendix 3G - Issue of Options		30/03/21	372.32KB	Share
PYC	PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board		29/03/21	163.74KB	Share
PYC	Director Retirement		26/03/21	217.61KB	Share
PYC	Appendix 3G - Issue of Options		25/03/21	394.25KB	Share
PYC	Initial Director's Interest Notice		23/03/21	297.46KB	Share
PYC	Participation in SVB Leerink Biopharma Private Co Connect		22/03/21	157.63KB	Share
PYC	PYC Appoints US Biotech Veteran to its Board of Directors		17/03/21	227.18KB	Share
PYC	Lead Investigational Drug Demonstrates Key Improvement	PRICE SENSITIVE	02/03/21	561.42KB	Share
PYC	Half Year Accounts and Appendix 4D	PRICE SENSITIVE	26/02/21	695.29KB	Share
PYC	PYC Expands US Executive Leadership Team		23/02/21	195.56KB	Share
PYC	Progress US Clinical Stage Company and Corporate Objectives	PRICE SENSITIVE	22/02/21	243.93KB	Share
PYC	Change of Director's Interest Notice		19/02/21	269.89KB	Share
PYC	PYC to Participate in RNA Discussion - CEO BIO Conference		11/02/21	200.12KB	Share
PYC	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/01/21	424.49KB	Share

PYC Q1 Investor Call 17 February 2023
10/02/23		188.48KB	Share
PYC PYC Corporate Presentation - February 2023
03/02/23		2.82MB	Share
PYC VP-001 IND Lodgement
02/02/23	PRICE SENSITIVE	158.05KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
20/01/23	PRICE SENSITIVE	223.22KB	Share
PYC Notification of cessation of securities - PYC
21/12/22		23.83KB	Share
PYC PYC Increases Ownership of VP-001 Program
29/11/22	PRICE SENSITIVE	163.64KB	Share
PYC Results of Annual General Meeting
23/11/22		243.99KB	Share
PYC 2022 AGM Chairman's Address and CEO Presentation
23/11/22		1.76MB	Share
PYC Annual General Meeting - Conference Call
21/11/22		160.78KB	Share
PYC Successful Toxicology Studies Pave Way for Human Trials
07/11/22	PRICE SENSITIVE	223.45KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	446.75KB	Share
PYC Issue of Options
28/10/22		322.61KB	Share
PYC Notification regarding unquoted securities - PYC
28/10/22		27.57KB	Share
PYC Notice of Annual General Meeting/Proxy Form
14/10/22		832.75KB	Share
PYC PYC Presenting on Drug Delivery Platform at OTS 2022 Meeting
03/10/22		201.51KB	Share
PYC Central Nervous System Drug Program Added to PYC Pipeline
27/09/22	PRICE SENSITIVE	256.59KB	Share
PYC Corporate Governance Statement and Appendix 4G
23/09/22		670.25KB	Share
PYC Annual Report to shareholders
23/09/22		2.41MB	Share
PYC Preliminary Final Report
31/08/22	PRICE SENSITIVE	788.67KB	Share
PYC PYC Shareholder Update
18/08/22		603.36KB	Share
PYC Change of Director's Interest Notice
11/08/22		267.27KB	Share
PYC PYC Therapeutics Investor Call - 18 August 2022
09/08/22		193.48KB	Share
PYC Change of Director's Interest Notice
04/08/22		267.27KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
27/07/22	PRICE SENSITIVE	231.28KB	Share
PYC Share Trading Policy
28/06/22		426.93KB	Share
PYC Corporate Presentation - May 2022
31/05/22		728.83KB	Share
PYC PYC Q2 Investor Call - 31 May 2022
27/05/22		191.43KB	Share
PYC PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS
10/05/22		213.56KB	Share
PYC Appendix A Terms and Conditions of Options
04/05/22		123.22KB	Share
PYC Notification regarding unquoted securities - PYC
04/05/22		27.68KB	Share
PYC Issue of Options
04/05/22		179.56KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	238.74KB	Share
PYC Completes FDA Pre-IND engagement - RP11 program
23/03/22		190.45KB	Share
PYC Q1 Investor Call Presentation
17/03/22		278.21KB	Share
PYC Quarterly Investor Call March 2022
08/03/22		161.84KB	Share
PYC Notification regarding unquoted securities - PYC
01/03/22		27.41KB	Share
PYC Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	2.31MB	Share
PYC PYC Increases Shareholding in Vision Pharma
17/02/22	PRICE SENSITIVE	161.82KB	Share
PYC Becoming a substantial holder
02/02/22		310.61KB	Share
PYC Quarterly Activities and Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	212.81KB	Share
PYC Notification of cessation of securities - PYC
07/01/22		21.75KB	Share
PYC Change in substantial holding
29/12/21		538.01KB	Share
PYC Change of Registry Address
20/12/21		152.9KB	Share
PYC Notification of cessation of securities - PYC
09/12/21		21.73KB	Share
PYC Appendix C US Sub Plan
30/11/21		156.65KB	Share
PYC Appendix B Terms and Conditions of Options
30/11/21		136.4KB	Share
PYC Appendix A Terms and Conditions of Options
30/11/21		136.28KB	Share
PYC Notification regarding unquoted securities - PYC
30/11/21		30.48KB	Share
PYC Notification of cessation of securities - PYC
29/11/21		21.69KB	Share
PYC Final Director's Interest Notice
25/11/21		287.11KB	Share
PYC Results of 2021 Annual General Meeting
18/11/21		159.65KB	Share
PYC 2021 AGM Chairman's Address and CEO Presentation
18/11/21		294.09KB	Share
PYC Annual General Meeting - Conference Link
17/11/21		161.93KB	Share
PYC Successful Completion of Key Translational Milestone
16/11/21	PRICE SENSITIVE	190.99KB	Share
PYC Trading Halt
15/11/21	PRICE SENSITIVE	186.73KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	287.47KB	Share
PYC Notice of Annual General Meeting/Proxy Form
19/10/21		1.08MB	Share
PYC Retina Target Engagement Confirmed in Large Eye
29/09/21	PRICE SENSITIVE	316.13KB	Share
PYC Corporate Governance Statement and Appendix 4G
22/09/21		669.27KB	Share
PYC Annual Report to shareholders
22/09/21		1.72MB	Share
PYC Upcoming Poster Presentations at TIDES USA and OTS 2021
21/09/21		175.71KB	Share
PYC Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15/09/21		158.31KB	Share
PYC Preliminary Final Report
31/08/21	PRICE SENSITIVE	3.64MB	Share
PYC August Investor Update
17/08/21		1.51MB	Share
PYC Ophthalmology-Focused Clinical Advisory Board
17/08/21		174.51KB	Share
PYC PYC Quarterly Investor Call - August 17
11/08/21		191.28KB	Share
PYC Participation in Upcoming U.S. Investor Conferences
03/08/21		160.06KB	Share
PYC Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	407.7KB	Share
PYC Commencement of Larger Animal Studies for Lead Program
14/07/21		160.02KB	Share
PYC Change of Auditor
01/07/21		145.35KB	Share
PYC VP-002 Program - Technical Presentation
29/06/21		864.11KB	Share
PYC Exercise of Options
15/06/21		281.94KB	Share
PYC Application for quotation of securities - PYC
15/06/21		25.34KB	Share
PYC New U.S. Headquarters, and Residency at JLABS
15/06/21		163.29KB	Share
PYC Second Drug Program Progressing Towards Human Trials
08/06/21	PRICE SENSITIVE	389.99KB	Share
PYC Trading Halt
07/06/21	PRICE SENSITIVE	613.05KB	Share
PYC Evercore ISI GenomeRx Emerging Therapeutic Company Day
26/05/21		157.21KB	Share
PYC SECOND DRUG PROGRAM - EFFICACY DATA IN PATIENT CELL MODELS
18/05/21		289.67KB	Share
PYC PYC Invited to Present at ARVO 2021 Annual Meeting
04/05/21		175.83KB	Share
PYC Set To Announce Efficacy Results For Second Drug Program
03/05/21		193.64KB	Share
PYC March 2021 Quarterly Report and Cashflow
30/04/21	PRICE SENSITIVE	311.12KB	Share
PYC Corporate Presentation April 2021
22/04/21		2.57MB	Share
PYC April Investor Call Presentation
15/04/21		7.45MB	Share
PYC Preclinical Data - Superior PPMO Delivery to the Brain
12/04/21		2.68MB	Share
PYC Quarterly Investor Call - 15th April 2021
06/04/21		157.67KB	Share
PYC Appendix 3X - Initial Director's Interest Notice
30/03/21		302.3KB	Share
PYC Appendix 3G - Issue of Options
30/03/21		372.32KB	Share
PYC PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board
29/03/21		163.74KB	Share
PYC Director Retirement
26/03/21		217.61KB	Share
PYC Appendix 3G - Issue of Options
25/03/21		394.25KB	Share
PYC Initial Director's Interest Notice
23/03/21		297.46KB	Share
PYC Participation in SVB Leerink Biopharma Private Co Connect
22/03/21		157.63KB	Share
PYC PYC Appoints US Biotech Veteran to its Board of Directors
17/03/21		227.18KB	Share
PYC Lead Investigational Drug Demonstrates Key Improvement
02/03/21	PRICE SENSITIVE	561.42KB	Share
PYC Half Year Accounts and Appendix 4D
26/02/21	PRICE SENSITIVE	695.29KB	Share
PYC PYC Expands US Executive Leadership Team
23/02/21		195.56KB	Share
PYC Progress US Clinical Stage Company and Corporate Objectives
22/02/21	PRICE SENSITIVE	243.93KB	Share
PYC Change of Director's Interest Notice
19/02/21		269.89KB	Share
PYC PYC to Participate in RNA Discussion - CEO BIO Conference
11/02/21		200.12KB	Share
PYC Quarterly Activities Report and Appendix 4C
29/01/21	PRICE SENSITIVE	424.49KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.27		Change -0.055(4.15%)		Mkt cap ! $740.7M

Open	High	Low	Value	Volume
$1.30	$1.32	$1.24	$3.887M	3.083M

Buyers (Bids)

No.	Vol.	Price($)
3	7674	$1.26

Sellers (Offers)

Price($)	Vol.	No.
$1.28	3540	5

View Market Depth

No.	Vol.	Price($)
2	4847	1.270
1	10010	1.265
2	7381	1.260
2	10417	1.250
4	7144	1.240

Price($)	Vol.	No.
1.280	8003	9
1.285	3356	5
1.290	1175	2
1.295	4016	1
1.300	13317	3

Last trade - 15.42pm 11/08/2025 (20 minute delay)


Last $1.26		Change -0.055 ( 5.91 %)
Open	High	Low	Volume
$1.29	$1.30	$1.26	24662
Last updated 15.54pm 11/08/2025 ?

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories